Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis
Background: Suboptimal drug exposure in patients with drug-susceptible tuberculosis (DS-TB) can drive treatment failure. Pharmacodynamics (PD) biomarkers such as the plasma TB drug-activity (TDA) assay may guide dose finding studies and predict microbiological outcomes differently than conventional...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
| Series: | International Journal of Mycobacteriology |
| Subjects: | |
| Online Access: | http://www.ijmyco.org/article.asp?issn=2212-5531;year=2021;volume=10;issue=4;spage=457;epage=462;aulast=Said |
| _version_ | 1819283284222279680 |
|---|---|
| author | Bibie N Said Scott K Heysell Getnet Yimer Rob E Aarnoutse Gibson S Kibiki Stellah Mpagama Peter M Mbelele |
| author_facet | Bibie N Said Scott K Heysell Getnet Yimer Rob E Aarnoutse Gibson S Kibiki Stellah Mpagama Peter M Mbelele |
| author_sort | Bibie N Said |
| collection | DOAJ |
| description | Background: Suboptimal drug exposure in patients with drug-susceptible tuberculosis (DS-TB) can drive treatment failure. Pharmacodynamics (PD) biomarkers such as the plasma TB drug-activity (TDA) assay may guide dose finding studies and predict microbiological outcomes differently than conventional indices. Methods: A study was nested from phase 2b randomized double-blind controlled trial of Tanzanian patients who received a 600 mg, 900 mg, or 1200 mg with a standard dose for DS-TB. Serum at 6 weeks collected over 24-h at 2-h intervals was collected for rifampin area under the concentration–time curve relative to minimum inhibitory concentration (AUC0-24/MIC) or peak concentration and MIC (Cmax/MIC). TDA was the ratio of time-to-positive growth of the patient's Mycobacterium tuberculosis isolates with and without coculture of patient's plasma collected at Cmax. Spearman's rank correlation (r) between PD parameters and culture convention on both liquid and solid culture media. Results: Among 10 patients, 600 mg (3), 900 mg (3), and 1200 mg (4) of rifampin dosages. The mean ± standard deviation (SD) of AUC0-24/MIC for patients on 600 mg was 168 ± 159 mg·h/L, on 900 mg was 169 ± 166 mg·h/L, and on 1200 mg was 308 ± 238 mg·h/L. The mean-TDA (SD) was 2.56 (±0.75), 1.5 (±0.59), and 2.29 (±1.08) for patients on 600 mg, 900 mg, and 1200 mg rifampin doses, respectively. Higher TDA values correlated with faster time to culture convention on both liquid (r = −0.55, P = 0.099) and solid media (r = −0.65, P = 0.04). Conclusions: TDA and rifampin AUC0-24/MIC did not trend as expected with rifampin dose, but TDA better predicted the time to sputum culture conversion. TDA may provide additional discrimination in predicting treatment response for some regimens distinct from plasma exposure relative to MIC or mg/kg dose. |
| first_indexed | 2024-12-24T01:29:02Z |
| format | Article |
| id | doaj.art-0f51216d379d4e0699fd186dd57e9372 |
| institution | Directory Open Access Journal |
| issn | 2212-5531 2212-554X |
| language | English |
| last_indexed | 2024-12-24T01:29:02Z |
| publishDate | 2021-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | International Journal of Mycobacteriology |
| spelling | doaj.art-0f51216d379d4e0699fd186dd57e93722022-12-21T17:22:24ZengWolters Kluwer Medknow PublicationsInternational Journal of Mycobacteriology2212-55312212-554X2021-01-0110445746210.4103/ijmy.ijmy_178_21Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosisBibie N SaidScott K HeysellGetnet YimerRob E AarnoutseGibson S KibikiStellah MpagamaPeter M MbeleleBackground: Suboptimal drug exposure in patients with drug-susceptible tuberculosis (DS-TB) can drive treatment failure. Pharmacodynamics (PD) biomarkers such as the plasma TB drug-activity (TDA) assay may guide dose finding studies and predict microbiological outcomes differently than conventional indices. Methods: A study was nested from phase 2b randomized double-blind controlled trial of Tanzanian patients who received a 600 mg, 900 mg, or 1200 mg with a standard dose for DS-TB. Serum at 6 weeks collected over 24-h at 2-h intervals was collected for rifampin area under the concentration–time curve relative to minimum inhibitory concentration (AUC0-24/MIC) or peak concentration and MIC (Cmax/MIC). TDA was the ratio of time-to-positive growth of the patient's Mycobacterium tuberculosis isolates with and without coculture of patient's plasma collected at Cmax. Spearman's rank correlation (r) between PD parameters and culture convention on both liquid and solid culture media. Results: Among 10 patients, 600 mg (3), 900 mg (3), and 1200 mg (4) of rifampin dosages. The mean ± standard deviation (SD) of AUC0-24/MIC for patients on 600 mg was 168 ± 159 mg·h/L, on 900 mg was 169 ± 166 mg·h/L, and on 1200 mg was 308 ± 238 mg·h/L. The mean-TDA (SD) was 2.56 (±0.75), 1.5 (±0.59), and 2.29 (±1.08) for patients on 600 mg, 900 mg, and 1200 mg rifampin doses, respectively. Higher TDA values correlated with faster time to culture convention on both liquid (r = −0.55, P = 0.099) and solid media (r = −0.65, P = 0.04). Conclusions: TDA and rifampin AUC0-24/MIC did not trend as expected with rifampin dose, but TDA better predicted the time to sputum culture conversion. TDA may provide additional discrimination in predicting treatment response for some regimens distinct from plasma exposure relative to MIC or mg/kg dose.http://www.ijmyco.org/article.asp?issn=2212-5531;year=2021;volume=10;issue=4;spage=457;epage=462;aulast=Saidmycobacterial activitypharmacodynamic biomarkerstuberculosistuberculosis drug activity |
| spellingShingle | Bibie N Said Scott K Heysell Getnet Yimer Rob E Aarnoutse Gibson S Kibiki Stellah Mpagama Peter M Mbelele Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis International Journal of Mycobacteriology mycobacterial activity pharmacodynamic biomarkers tuberculosis tuberculosis drug activity |
| title | Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis |
| title_full | Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis |
| title_fullStr | Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis |
| title_full_unstemmed | Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis |
| title_short | Pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin-susceptible pulmonary tuberculosis |
| title_sort | pharmacodynamic biomarkers for quantifying the mycobacterial effect of high doses of rifampin in patients with rifampin susceptible pulmonary tuberculosis |
| topic | mycobacterial activity pharmacodynamic biomarkers tuberculosis tuberculosis drug activity |
| url | http://www.ijmyco.org/article.asp?issn=2212-5531;year=2021;volume=10;issue=4;spage=457;epage=462;aulast=Said |
| work_keys_str_mv | AT bibiensaid pharmacodynamicbiomarkersforquantifyingthemycobacterialeffectofhighdosesofrifampininpatientswithrifampinsusceptiblepulmonarytuberculosis AT scottkheysell pharmacodynamicbiomarkersforquantifyingthemycobacterialeffectofhighdosesofrifampininpatientswithrifampinsusceptiblepulmonarytuberculosis AT getnetyimer pharmacodynamicbiomarkersforquantifyingthemycobacterialeffectofhighdosesofrifampininpatientswithrifampinsusceptiblepulmonarytuberculosis AT robeaarnoutse pharmacodynamicbiomarkersforquantifyingthemycobacterialeffectofhighdosesofrifampininpatientswithrifampinsusceptiblepulmonarytuberculosis AT gibsonskibiki pharmacodynamicbiomarkersforquantifyingthemycobacterialeffectofhighdosesofrifampininpatientswithrifampinsusceptiblepulmonarytuberculosis AT stellahmpagama pharmacodynamicbiomarkersforquantifyingthemycobacterialeffectofhighdosesofrifampininpatientswithrifampinsusceptiblepulmonarytuberculosis AT petermmbelele pharmacodynamicbiomarkersforquantifyingthemycobacterialeffectofhighdosesofrifampininpatientswithrifampinsusceptiblepulmonarytuberculosis |